293 related articles for article (PubMed ID: 12860945)
1. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.
Faiss S; Pape UF; Böhmig M; Dörffel Y; Mansmann U; Golder W; Riecken EO; Wiedenmann B;
J Clin Oncol; 2003 Jul; 21(14):2689-96. PubMed ID: 12860945
[TBL] [Abstract][Full Text] [Related]
2. The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.
Michael M; Garcia-Carbonero R; Weber MM; Lombard-Bohas C; Toumpanakis C; Hicks RJ
Oncologist; 2017 Mar; 22(3):272-285. PubMed ID: 28220021
[TBL] [Abstract][Full Text] [Related]
3. Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study.
Pavel M; Lahner H; Hörsch D; Rinke A; Denecke T; Koch A; Regnault B; Helbig D; Hoffmanns P; Raderer M
Oncologist; 2024 May; 29(5):e643-e654. PubMed ID: 38206830
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.
Caplin ME; Pavel M; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Langley A; Martinez S; Gomez-Panzani E; Ruszniewski P;
Endocr Relat Cancer; 2016 Mar; 23(3):191-9. PubMed ID: 26743120
[TBL] [Abstract][Full Text] [Related]
5. Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study.
Kulke MH; Benson AB; Dasari A; Huynh L; Cai B; Totev T; Roesner N; Duh MS; Neary MP; Maurer VE; Shih BE; Dagohoy CG; Chan J; Bergsland EK
Oncologist; 2019 Aug; 24(8):1056-1065. PubMed ID: 30606883
[TBL] [Abstract][Full Text] [Related]
6. Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story.
Faggiano A
J Endocrinol Invest; 2024 Jan; 47(1):35-46. PubMed ID: 37581846
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and efficacy of lanreotide autogel in Japanese patients with neuroendocrine tumors: Final results of a phase II open-label extension study.
Ito T; Fujimori N; Honma Y; Kudo A; Hijioka S; Katsushima S; Kimura Y; Fukutomi A; Hisamatsu S; Nakajima A; Shimatsu A
Asia Pac J Clin Oncol; 2021 Oct; 17(5):e153-e161. PubMed ID: 32757459
[TBL] [Abstract][Full Text] [Related]
8. Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial.
Corti F; Brizzi MP; Amoroso V; Giuffrida D; Panzuto F; Campana D; Prinzi N; Milione M; Cascella T; Spreafico C; Randon G; Oldani S; Leporati R; Scotto G; Pulice I; Stocchetti BL; Porcu L; Coppa J; Di Bartolomeo M; de Braud F; Pusceddu S
BMC Cancer; 2023 Sep; 23(1):908. PubMed ID: 37752423
[TBL] [Abstract][Full Text] [Related]
9. Pituitary apoplexy in endocrinologically silent adenoma during somatostatin analog administration for pancreatic neuroendocrine tumor: A case report.
Shiraishi K; Akai T; Tomita T; Hayashi R; Minamisaka T; Kuroda S
Neuropathology; 2024 Jun; 44(3):247-251. PubMed ID: 38099404
[TBL] [Abstract][Full Text] [Related]
10. Patterns of Care Among Real-World Patients with Metastatic Neuroendocrine Tumors.
Klink AJ; Feinberg B; Yu HT; Ray D; Pulgar S; Phan A; Vinik A
Oncologist; 2019 Oct; 24(10):1331-1339. PubMed ID: 31015313
[TBL] [Abstract][Full Text] [Related]
11. A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors.
Raj N; Cruz E; O'Shaughnessy S; Calderon C; Chou JF; Capanu M; Heffernan O; DeMore A; Punn S; Le T; Hauser H; Saltz L; Reidy-Lagunes D
JCO Oncol Pract; 2022 Sep; 18(9):e1533-e1541. PubMed ID: 35724357
[TBL] [Abstract][Full Text] [Related]
12. Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors.
Saif MW; Parikh R; Ray D; Kaye JA; Kurosky SK; Thomas K; Ramirez RA; Halfdanarson TR; Beveridge TJR; Mirakhur B; Nagar SP; Soares HP
J Gastrointest Oncol; 2019 Aug; 10(4):674-687. PubMed ID: 31392048
[TBL] [Abstract][Full Text] [Related]
13. PREF-NET: a patient preference and experience study of lanreotide autogel administered in the home versus hospital setting among patients with gastroenteropancreatic neuroendocrine tumours in the UK.
Khan MS; Cook K; Weickert MO; Davies L; Pritchard DM; Day M; Shah T; Hull D; Caplin M; Back M; Pommie C; Higgs K
Support Care Cancer; 2024 Feb; 32(3):199. PubMed ID: 38421441
[TBL] [Abstract][Full Text] [Related]
14. Screening for malnutrition in patients with gastro-entero-pancreatic neuroendocrine tumours: a cross-sectional study.
Qureshi SA; Burch N; Druce M; Hattersley JG; Khan S; Gopalakrishnan K; Darby C; Wong JL; Davies L; Fletcher S; Shatwell W; Sothi S; Randeva HS; Dimitriadis GK; Weickert MO
BMJ Open; 2016 May; 6(5):e010765. PubMed ID: 27147385
[TBL] [Abstract][Full Text] [Related]
15. Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2.
Pusceddu S; Corti F; Prinzi N; Nichetti F; Ljevar S; Busico A; Cascella T; Leporati R; Oldani S; Pircher CC; Coppa J; Resi V; Milione M; Maccauro M; Miceli R; Tamborini E; Perrone F; Spreafico C; Niger M; Morano F; Pietrantonio F; Seregni E; Mariani L; Mazzaferro V; Di Liberti G; Fucà G; de Braud F; Vernieri C
J Hematol Oncol; 2023 Dec; 16(1):119. PubMed ID: 38098114
[TBL] [Abstract][Full Text] [Related]
16. Optimal first-line treatment strategies of systemic therapy for unresectable gastrointestinal neuroendocrine tumors based on the opinions of Japanese experts.
Honma Y; Ikeda M; Hijioka S; Matsumoto S; Ito T; Aoki T; Furuse J
Invest New Drugs; 2023 Dec; 41(6):777-786. PubMed ID: 37856005
[TBL] [Abstract][Full Text] [Related]
17. Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives.
Hijioka S; Morizane C; Ikeda M; Ishii H; Okusaka T; Furuse J
Jpn J Clin Oncol; 2021 Aug; 51(8):1185-1196. PubMed ID: 34038547
[TBL] [Abstract][Full Text] [Related]
18. Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals.
Ortendahl JD; Pulgar SJ; Mirakhur B; Cox D; Bentley TG; Phan AT
Clinicoecon Outcomes Res; 2017; 9():495-503. PubMed ID: 28860831
[TBL] [Abstract][Full Text] [Related]
19. Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors.
Bösch F; Bazhin AV; Heublein S; Brüwer K; Knösel T; Reiter FP; Auernhammer CJ; Guba MO; Spitzweg C; Werner J; Angele MK
BMC Cancer; 2019 Jun; 19(1):575. PubMed ID: 31196127
[TBL] [Abstract][Full Text] [Related]
20. OPERA: perception of information in patients with gastroenteropancreatic neuroendocrine tumors on lanreotide autogel.
Hautefeuille V; Walter T; Do Cao C; Coriat R; Dominguez S; Mineur L; Cadiot G; Terrebonne E; Sobhani I; Gueguen D; Houchard A; Mouawad C; Anota A; Hammel P
Eur J Endocrinol; 2023 Aug; 189(2):281-289. PubMed ID: 37542470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
